Establishing the scalable manufacture of primary human T‐cells in an automated stirred‐tank bioreactor
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Advanced cell and gene therapies such as chimeric antigen receptor T‐cell immunotherapies (CAR‐T), present a novel therapeutic modality for the treatment of acute and chronic conditions including acute lymphoblastic leukemia and non‐Hodgkin lymphoma. However, the development of such immunotherapies requires the manufacture of large numbers of T‐cells, which remains a major translational and commercial bottleneck due to the manual, small‐scale, and often static culturing systems used for their production. Such systems are used because there is an unsubstantiated concern that primary T‐cells are shear sensitive, or prefer static conditions, and therefore do not grow as effectively in more scalable, agitated systems, such as stirred‐tank bioreactors, as compared with T‐flasks and culture bags. In this study, we demonstrate that not only T‐cells can be cultivated in an automated stirred‐tank bioreactor system (ambr® 250), but that their growth is consistently and significantly better than that in T‐flask static culture, with equivalent cell quality. Moreover, we demonstrate that at progressively higher agitation rates over the range studied here, and thereby, higher specific power inputs (P/M W kg−1), the higher the final viable T‐cell density; that is, a cell density of 4.65 ± 0.24 × 10 6 viable cells ml−1 obtained at the highest P/M of 74 × 10−4 W kg−1 in comparison with 0.91 ± 0.07 × 10 6 viable cells ml−1 at the lowest P/M of 3.1 × 10−4 W kg−1. We posit that this improvement is due to the inability at the lower agitation rates to effectively suspend the Dynabeads®, which are required to activate the T‐cells; and that contact between them is improved at the higher agitation rates. Importantly, from the data obtained, there is no indication that T‐cells prefer being grown under static conditions or are sensitive to fluid dynamic stresses within a stirred‐tank bioreactor system at the agitation speeds investigated. Indeed, the opposite has proven to be the case, whereby, the cells grow better under higher agitation speeds while maintaining their quality. This study is the first demonstration of primary T‐cell ex vivo manufacture activated by Dynabeads® in an automated stirred‐tank bioreactor system such as the ambr® 250 and the findings have the potential to be applied to multiple other cell candidates for advanced therapy applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Cited by
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321
Needle to needle robot‐assisted manufacture of cell therapy products
Ochs, J., Hanga, M. P., Shaw, G., Duffy, N., Kulik, M., Tissin, N., Reibert, D., Biermann, F., Moutsatsou, P., Ratnayake, S., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10387 · Cited by 18
Self-citationSyed, F., El Fakih, R., Alahmari, A. D., Ali, A. S. O., & Aljurf, M. (2022) · Hematology/Oncology and Stem Cell Therapy · doi:10.56875/2589-0646.1048 · Cited by 18
Egan, J. R., Marí‐Buyé, N., Benítez‐Cano, E. V., Costa, M., Wanika, L., Chappell, M. J., Schultz, U., Ochs, J., Effenberger, M., Horna, D., et al. (2025) · Biotechnology Progress · doi:10.1002/btpr.70045 · Cited by 10
Self-citation
Metadata
- Authors
- Costariol, E., Rotondi, M., Amini, A., Hewitt, C. J., Nienow, A. W., Heathman, T. R. J., Micheletti, M., & Rafiq, Q. A.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2019-07-09
- Volume
- 116
- Issue
- 10
- Pages
- 2488-2502
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2951554930
- Cited by
- 40
- References
- 2
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Establishing the scalable manufacture of primary human T‐cells in an automated stirred‐tank bioreactor. https://app.cochat.ai/papers/10.1002/bit.27088
- The paper
- Costariol, E., Rotondi, M., Amini, A., Hewitt, C. J., Nienow, A. W., Heathman, T. R. J., Micheletti, M., & Rafiq, Q. A. (2019). Establishing the scalable manufacture of primary human T‐cells in an automated stirred‐tank bioreactor. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.27088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.